Active Ingredient History
Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Zidovudine, a structural analog of thymidine, is a prodrug that must be phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). It inhibits the activity of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. It competes with the natural substrate dGTP and incorporates itself into viral DNA. It is also a weak inhibitor of cellular DNA polymerase α and γ. Zidovudine is used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections. Zidovudine is marketed as Retrovir. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 4)
Acute Febrile Encephalopathy (Phase 2)
Aicardi Syndrome (Phase 2)
AIDS Dementia Complex (Phase 3)
AIDS-Related Complex (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 1)
Atrophy (Phase 4)
Brain Diseases (Phase 2)
Breast Feeding (Phase 3)
Cardiovascular Diseases (Phase 4)
Castleman Disease (Phase 2)
Central Nervous System Diseases (Phase 4)
Cytomegalovirus Infections (Phase 1)
Deficiency Diseases (Phase 3)
Dementia (Phase 4)
Diabetes Mellitus (Phase 4)
Diarrhea (Phase 3)
DNA, Mitochondrial (Phase 2)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 4)
Glucose Metabolism Disorders (Phase 4)
Gout (Phase 2)
Healthy Volunteers (Phase 1)
Hemophilia A (Phase 4)
Hepatitis B (Phase 4)
Hepatitis C (Phase 4)
Herpesvirus 8, Human (Phase 2)
HIV (Phase 4)
HIV-1 (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 4)
HIV Seropositivity (Phase 2)
Hodgkin Disease (Phase 2)
HTLV-I Infections (Early Phase 1)
Hypercholesterolemia (Phase 4)
Insulin Resistance (Phase 4)
Kidney Diseases (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Lipodystrophy (Phase 4)
Liver Cirrhosis, Biliary (Phase 2/Phase 3)
Liver Diseases (Phase 4)
Lymphoma (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Malaria (Phase 3)
Malnutrition (Phase 4)
Metabolic Diseases (Phase 4)
Metabolism (Phase 2)
Mitochondrial Diseases (Phase 2)
Mitochondrial Encephalomyopathies (Phase 2)
Neoplasms (Phase 2)
Paraparesis, Tropical Spastic (Phase 2/Phase 3)
Pneumonia, Pneumocystis (Phase 3)
Precancerous Conditions (Phase 1/Phase 2)
Pregnancy (Phase 3)
Proteinuria (Phase 4)
Sarcoma, Kaposi (Phase 2/Phase 3)
Thrombocytopenia (Phase 1)
Thymidine Kinase (Phase 2)
Toxoplasmosis, Cerebral (Phase 1)
Tuberculosis (Phase 4)
Zidovudine (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
